Mitochondrial Fusion Transcript Detection via Hybridization Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and diagnostic tools for cancer using mitochondrial fusion transcripts and proteins, which are potential biomarkers for cancer diagnosis.
Innovation Solution
Development of isolated mitochondrial fusion transcripts, mtDNA encoding these transcripts, hybridization probes complementary to these transcripts, and methods for detecting cancer in mammals by assaying tissue samples for the presence of these transcripts or proteins using hybridization probes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer detection methods are used, then existing diagnostic capabilities are maintained, but the ability to detect cancer using mitochondrial fusion transcripts and proteins is lacking
Solution Approach 1:
The patent performs preliminary identification and characterization of mitochondrial fusion transcripts and proteins before clinical application. Specific fusion transcripts (e.g., ND4L-ND5, COII-Cytb) and their encoded proteins are identified and characterized in advance, allowing development of targeted detection methods before actual cancer diagnosis is performed.
Solution Approach 2:
The patent uses hybridization probes as intermediary molecules to detect mitochondrial fusion transcripts. These probes serve as mediators that specifically bind to target fusion transcripts, enabling indirect detection of cancer-related mitochondrial abnormalities without directly observing the pathological changes.
2Reliability
If mitochondrial fusion transcripts are used as biomarkers, then cancer prediction and diagnosis capability is improved, but the complexity of identifying and analyzing these transcripts increases
Solution Approach 1:
The patent segments the complex mitochondrial genome into specific fusion transcript regions for targeted analysis. Instead of analyzing the entire mitochondrial genome, specific fusion transcripts (e.g., ND4L-ND5, COII-Cytb, ATPase6-Cytb) are identified and analyzed separately, simplifying the detection process while maintaining diagnostic reliability.
Solution Approach 2:
The patent develops a universal detection approach using hybridization probes that can detect multiple different mitochondrial fusion transcripts with a single methodology. The same basic probe-based detection system can be applied to various fusion transcripts and different cancer types, reducing overall system complexity through method standardization.
3Ease of manufacture
If mitochondrial deletions are considered merely deleterious by-products, then the complexity of understanding mitochondrial genome dynamics is reduced, but the functional role of these deletions in cancer pathways is overlooked
Solution Approach 1:
The patent converts the previously harmful mitochondrial deletions into beneficial diagnostic information. Instead of viewing deletions merely as damage to be eliminated, the invention identifies specific deletion patterns and resulting fusion transcripts as valuable cancer biomarkers, transforming a pathological feature into a diagnostic advantage.
Solution Approach 2:
The patent inverts the conventional view of mitochondrial deletions from harmful by-products to functional biomarkers. Rather than seeing deletions as errors to be corrected, the invention analyzes the resulting fusion transcripts and proteins as informative indicators of cancer, reversing the traditional interpretation of mitochondrial genome abnormalities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables the prediction, diagnosis, and monitoring of cancer by identifying specific mitochondrial fusion transcripts and proteins, providing a novel approach for cancer detection and management.
Implementation Method 1
hybridization probes complementary to these transcripts, and methods for detecting cancer in mammals by assaying tissue samples for the presence of these transcripts or proteins using hybridization probes
Data Source
Figure 1~2
Figure 3~4
Figure 5a~5b
AI summary
The present invention provides novel mitochondrial fusion transcripts, the parent mutated mtDNA molecules, and the resulting translation products (proteins) for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.